Click chemistry enables preclinical evaluation of targeted epigenetic therapies.
Identifieur interne : 004991 ( Ncbi/Curation ); précédent : 004990; suivant : 004992Click chemistry enables preclinical evaluation of targeted epigenetic therapies.
Auteurs : Dean S. Tyler [Australie] ; Johanna Vappiani [Allemagne] ; Tatiana Ca Eque [France] ; Enid Y N. Lam [Australie] ; Aoife Ward [Allemagne] ; Omer Gilan [Australie] ; Yih-Chih Chan [Australie] ; Antje Hienzsch [France] ; Anna Rutkowska [Allemagne] ; Thilo Werner [Allemagne] ; Anne J. Wagner [Allemagne] ; Dave Lugo [Royaume-Uni] ; Richard Gregory [Royaume-Uni] ; Cesar Ramirez Molina [Royaume-Uni] ; Neil Garton [Royaume-Uni] ; Christopher R. Wellaway [Royaume-Uni] ; Susan Jackson [Australie] ; Laura Macpherson [Australie] ; Margarida Figueiredo [Australie] ; Sabine Stolzenburg [Australie] ; Charles C. Bell [Australie] ; Colin House [Australie] ; Sarah-Jane Dawson [Australie] ; Edwin D. Hawkins [Australie] ; Gerard Drewes [Allemagne] ; Rab K. Prinjha [Royaume-Uni] ; Raphaël Rodriguez [France] ; Paola Grandi [Allemagne] ; Mark A. Dawson [Australie]Source :
- Science (New York, N.Y.) [ 1095-9203 ] ; 2017.
Abstract
The success of new therapies hinges on our ability to understand their molecular and cellular mechanisms of action. We modified BET bromodomain inhibitors, an epigenetic-based therapy, to create functionally conserved compounds that are amenable to click chemistry and can be used as molecular probes in vitro and in vivo. We used click proteomics and click sequencing to explore the gene regulatory function of BRD4 (bromodomain containing protein 4) and the transcriptional changes induced by BET inhibitors. In our studies of mouse models of acute leukemia, we used high-resolution microscopy and flow cytometry to highlight the heterogeneity of drug activity within tumor cells located in different tissue compartments. We also demonstrate the differential distribution and effects of BET inhibitors in normal and malignant cells in vivo. This study provides a potential framework for the preclinical assessment of a wide range of drugs.
DOI: 10.1126/science.aal2066
PubMed: 28619718
Links toward previous steps (curation, corpus...)
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A21
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :000A18
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000A18
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :004991
Links to Exploration step
pubmed:28619718Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Click chemistry enables preclinical evaluation of targeted epigenetic therapies.</title><author><name sortKey="Tyler, Dean S" sort="Tyler, Dean S" uniqKey="Tyler D" first="Dean S" last="Tyler">Dean S. Tyler</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Vappiani, Johanna" sort="Vappiani, Johanna" uniqKey="Vappiani J" first="Johanna" last="Vappiani">Johanna Vappiani</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Ca Eque, Tatiana" sort="Ca Eque, Tatiana" uniqKey="Ca Eque T" first="Tatiana" last="Ca Eque">Tatiana Ca Eque</name><affiliation wicri:level="1"><nlm:affiliation>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05</wicri:regionArea><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion></affiliation></author><author><name sortKey="Lam, Enid Y N" sort="Lam, Enid Y N" uniqKey="Lam E" first="Enid Y N" last="Lam">Enid Y N. Lam</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Ward, Aoife" sort="Ward, Aoife" uniqKey="Ward A" first="Aoife" last="Ward">Aoife Ward</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Gilan, Omer" sort="Gilan, Omer" uniqKey="Gilan O" first="Omer" last="Gilan">Omer Gilan</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Yih Chih" sort="Chan, Yih Chih" uniqKey="Chan Y" first="Yih-Chih" last="Chan">Yih-Chih Chan</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Hienzsch, Antje" sort="Hienzsch, Antje" uniqKey="Hienzsch A" first="Antje" last="Hienzsch">Antje Hienzsch</name><affiliation wicri:level="1"><nlm:affiliation>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05</wicri:regionArea><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion></affiliation></author><author><name sortKey="Rutkowska, Anna" sort="Rutkowska, Anna" uniqKey="Rutkowska A" first="Anna" last="Rutkowska">Anna Rutkowska</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Werner, Thilo" sort="Werner, Thilo" uniqKey="Werner T" first="Thilo" last="Werner">Thilo Werner</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Wagner, Anne J" sort="Wagner, Anne J" uniqKey="Wagner A" first="Anne J" last="Wagner">Anne J. Wagner</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Lugo, Dave" sort="Lugo, Dave" uniqKey="Lugo D" first="Dave" last="Lugo">Dave Lugo</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Gregory, Richard" sort="Gregory, Richard" uniqKey="Gregory R" first="Richard" last="Gregory">Richard Gregory</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Ramirez Molina, Cesar" sort="Ramirez Molina, Cesar" uniqKey="Ramirez Molina C" first="Cesar" last="Ramirez Molina">Cesar Ramirez Molina</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Garton, Neil" sort="Garton, Neil" uniqKey="Garton N" first="Neil" last="Garton">Neil Garton</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Wellaway, Christopher R" sort="Wellaway, Christopher R" uniqKey="Wellaway C" first="Christopher R" last="Wellaway">Christopher R. Wellaway</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Susan" sort="Jackson, Susan" uniqKey="Jackson S" first="Susan" last="Jackson">Susan Jackson</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Macpherson, Laura" sort="Macpherson, Laura" uniqKey="Macpherson L" first="Laura" last="Macpherson">Laura Macpherson</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Figueiredo, Margarida" sort="Figueiredo, Margarida" uniqKey="Figueiredo M" first="Margarida" last="Figueiredo">Margarida Figueiredo</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Stolzenburg, Sabine" sort="Stolzenburg, Sabine" uniqKey="Stolzenburg S" first="Sabine" last="Stolzenburg">Sabine Stolzenburg</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Bell, Charles C" sort="Bell, Charles C" uniqKey="Bell C" first="Charles C" last="Bell">Charles C. Bell</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="House, Colin" sort="House, Colin" uniqKey="House C" first="Colin" last="House">Colin House</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Dawson, Sarah Jane" sort="Dawson, Sarah Jane" uniqKey="Dawson S" first="Sarah-Jane" last="Dawson">Sarah-Jane Dawson</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Hawkins, Edwin D" sort="Hawkins, Edwin D" uniqKey="Hawkins E" first="Edwin D" last="Hawkins">Edwin D. Hawkins</name><affiliation wicri:level="1"><nlm:affiliation>The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Drewes, Gerard" sort="Drewes, Gerard" uniqKey="Drewes G" first="Gerard" last="Drewes">Gerard Drewes</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Prinjha, Rab K" sort="Prinjha, Rab K" uniqKey="Prinjha R" first="Rab K" last="Prinjha">Rab K. Prinjha</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Rodriguez, Raphael" sort="Rodriguez, Raphael" uniqKey="Rodriguez R" first="Raphaël" last="Rodriguez">Raphaël Rodriguez</name><affiliation wicri:level="1"><nlm:affiliation>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05</wicri:regionArea><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion></affiliation></author><author><name sortKey="Grandi, Paola" sort="Grandi, Paola" uniqKey="Grandi P" first="Paola" last="Grandi">Paola Grandi</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany. paola.x.grandi@gsk.com mark.dawson@petermac.org.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Dawson, Mark A" sort="Dawson, Mark A" uniqKey="Dawson M" first="Mark A" last="Dawson">Mark A. Dawson</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. paola.x.grandi@gsk.com mark.dawson@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2017">2017</date><idno type="RBID">pubmed:28619718</idno><idno type="pmid">28619718</idno><idno type="doi">10.1126/science.aal2066</idno><idno type="wicri:Area/PubMed/Corpus">000A21</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000A21</idno><idno type="wicri:Area/PubMed/Curation">000A18</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">000A18</idno><idno type="wicri:Area/PubMed/Checkpoint">000A18</idno><idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">000A18</idno><idno type="wicri:Area/Ncbi/Merge">004991</idno><idno type="wicri:Area/Ncbi/Curation">004991</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Click chemistry enables preclinical evaluation of targeted epigenetic therapies.</title><author><name sortKey="Tyler, Dean S" sort="Tyler, Dean S" uniqKey="Tyler D" first="Dean S" last="Tyler">Dean S. Tyler</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Vappiani, Johanna" sort="Vappiani, Johanna" uniqKey="Vappiani J" first="Johanna" last="Vappiani">Johanna Vappiani</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Ca Eque, Tatiana" sort="Ca Eque, Tatiana" uniqKey="Ca Eque T" first="Tatiana" last="Ca Eque">Tatiana Ca Eque</name><affiliation wicri:level="1"><nlm:affiliation>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05</wicri:regionArea><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion></affiliation></author><author><name sortKey="Lam, Enid Y N" sort="Lam, Enid Y N" uniqKey="Lam E" first="Enid Y N" last="Lam">Enid Y N. Lam</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Ward, Aoife" sort="Ward, Aoife" uniqKey="Ward A" first="Aoife" last="Ward">Aoife Ward</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Gilan, Omer" sort="Gilan, Omer" uniqKey="Gilan O" first="Omer" last="Gilan">Omer Gilan</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Chan, Yih Chih" sort="Chan, Yih Chih" uniqKey="Chan Y" first="Yih-Chih" last="Chan">Yih-Chih Chan</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Hienzsch, Antje" sort="Hienzsch, Antje" uniqKey="Hienzsch A" first="Antje" last="Hienzsch">Antje Hienzsch</name><affiliation wicri:level="1"><nlm:affiliation>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05</wicri:regionArea><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion></affiliation></author><author><name sortKey="Rutkowska, Anna" sort="Rutkowska, Anna" uniqKey="Rutkowska A" first="Anna" last="Rutkowska">Anna Rutkowska</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Werner, Thilo" sort="Werner, Thilo" uniqKey="Werner T" first="Thilo" last="Werner">Thilo Werner</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Wagner, Anne J" sort="Wagner, Anne J" uniqKey="Wagner A" first="Anne J" last="Wagner">Anne J. Wagner</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Lugo, Dave" sort="Lugo, Dave" uniqKey="Lugo D" first="Dave" last="Lugo">Dave Lugo</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Gregory, Richard" sort="Gregory, Richard" uniqKey="Gregory R" first="Richard" last="Gregory">Richard Gregory</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Ramirez Molina, Cesar" sort="Ramirez Molina, Cesar" uniqKey="Ramirez Molina C" first="Cesar" last="Ramirez Molina">Cesar Ramirez Molina</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Garton, Neil" sort="Garton, Neil" uniqKey="Garton N" first="Neil" last="Garton">Neil Garton</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Wellaway, Christopher R" sort="Wellaway, Christopher R" uniqKey="Wellaway C" first="Christopher R" last="Wellaway">Christopher R. Wellaway</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Jackson, Susan" sort="Jackson, Susan" uniqKey="Jackson S" first="Susan" last="Jackson">Susan Jackson</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Macpherson, Laura" sort="Macpherson, Laura" uniqKey="Macpherson L" first="Laura" last="Macpherson">Laura Macpherson</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Figueiredo, Margarida" sort="Figueiredo, Margarida" uniqKey="Figueiredo M" first="Margarida" last="Figueiredo">Margarida Figueiredo</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Stolzenburg, Sabine" sort="Stolzenburg, Sabine" uniqKey="Stolzenburg S" first="Sabine" last="Stolzenburg">Sabine Stolzenburg</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Bell, Charles C" sort="Bell, Charles C" uniqKey="Bell C" first="Charles C" last="Bell">Charles C. Bell</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="House, Colin" sort="House, Colin" uniqKey="House C" first="Colin" last="House">Colin House</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Dawson, Sarah Jane" sort="Dawson, Sarah Jane" uniqKey="Dawson S" first="Sarah-Jane" last="Dawson">Sarah-Jane Dawson</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Hawkins, Edwin D" sort="Hawkins, Edwin D" uniqKey="Hawkins E" first="Edwin D" last="Hawkins">Edwin D. Hawkins</name><affiliation wicri:level="1"><nlm:affiliation>The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>The Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author><author><name sortKey="Drewes, Gerard" sort="Drewes, Gerard" uniqKey="Drewes G" first="Gerard" last="Drewes">Gerard Drewes</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Prinjha, Rab K" sort="Prinjha, Rab K" uniqKey="Prinjha R" first="Rab K" last="Prinjha">Rab K. Prinjha</name><affiliation wicri:level="1"><nlm:affiliation>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage, UK.</nlm:affiliation><country xml:lang="fr">Royaume-Uni</country><wicri:regionArea>Epigenetics Discovery Performance Unit, Immuno-Inflammation Therapy Area Unit, GlaxoSmithKline, Stevenage</wicri:regionArea><wicri:noRegion>Stevenage</wicri:noRegion></affiliation></author><author><name sortKey="Rodriguez, Raphael" sort="Rodriguez, Raphael" uniqKey="Rodriguez R" first="Raphaël" last="Rodriguez">Raphaël Rodriguez</name><affiliation wicri:level="1"><nlm:affiliation>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05, France.</nlm:affiliation><country xml:lang="fr">France</country><wicri:regionArea>Chemical Cell Biology Group, Institut Curie, Paris Sciences et Lettres Research University, 26 Rue d'Ulm, 75248 Paris Cedex 05</wicri:regionArea><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion><wicri:noRegion>75248 Paris Cedex 05</wicri:noRegion></affiliation></author><author><name sortKey="Grandi, Paola" sort="Grandi, Paola" uniqKey="Grandi P" first="Paola" last="Grandi">Paola Grandi</name><affiliation wicri:level="3"><nlm:affiliation>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg, Germany. paola.x.grandi@gsk.com mark.dawson@petermac.org.</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Cellzome GmbH, GlaxoSmithKline, Meyerhofstrasse 1, Heidelberg</wicri:regionArea><placeName><region type="land" nuts="1">Bade-Wurtemberg</region><region type="district" nuts="2">District de Karlsruhe</region><settlement type="city">Heidelberg</settlement></placeName></affiliation></author><author><name sortKey="Dawson, Mark A" sort="Dawson, Mark A" uniqKey="Dawson M" first="Mark A" last="Dawson">Mark A. Dawson</name><affiliation wicri:level="1"><nlm:affiliation>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia. paola.x.grandi@gsk.com mark.dawson@petermac.org.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Cancer Research Division, Peter MacCallum Cancer Centre, Melbourne, Victoria</wicri:regionArea><wicri:noRegion>Victoria</wicri:noRegion></affiliation></author></analytic><series><title level="j">Science (New York, N.Y.)</title><idno type="eISSN">1095-9203</idno><imprint><date when="2017" type="published">2017</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">The success of new therapies hinges on our ability to understand their molecular and cellular mechanisms of action. We modified BET bromodomain inhibitors, an epigenetic-based therapy, to create functionally conserved compounds that are amenable to click chemistry and can be used as molecular probes in vitro and in vivo. We used click proteomics and click sequencing to explore the gene regulatory function of BRD4 (bromodomain containing protein 4) and the transcriptional changes induced by BET inhibitors. In our studies of mouse models of acute leukemia, we used high-resolution microscopy and flow cytometry to highlight the heterogeneity of drug activity within tumor cells located in different tissue compartments. We also demonstrate the differential distribution and effects of BET inhibitors in normal and malignant cells in vivo. This study provides a potential framework for the preclinical assessment of a wide range of drugs.</div></front></TEI></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 004991 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 004991 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= Ncbi
|étape= Curation
|type= RBID
|clé= pubmed:28619718
|texte= Click chemistry enables preclinical evaluation of targeted epigenetic therapies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i -Sk "pubmed:28619718" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |